ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...
It would be short-sided, erroneous and dangerous to think ill of mifepristone, which has several important applications,, M.D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback